Incretin and metabolic peptides studied for glycemic control and fat loss.
Metabolic peptides are among the most clinically validated classes in modern medicine. The incretin axis — GLP-1, GIP, and glucagon receptor signaling — coordinates insulin secretion, satiety, gastric emptying, and energy expenditure, and engineered agonists of these receptors now anchor the treatment of type 2 diabetes and obesity.
Research in this area spans single-, dual-, and triple-receptor agonists, amylin analogs, and adipose-selective fragments. Endpoints commonly studied include glycemic control, body-weight reduction, MASH/hepatic-fat resolution, and cardiovascular risk — with half-life extension (fatty-acid acylation, DPP-4 resistance) a recurring engineering theme.
Long-acting GLP-1 receptor agonist for glycemic control and weight management.
View profileDual GIP / GLP-1 receptor agonist with industry-leading weight-loss endpoints.
View profileInvestigational triple agonist (GIP / GLP-1 / glucagon) in late-stage trials.
View profileLong-acting amylin analog studied alongside semaglutide as CagriSema.
View profileGHRH analog FDA-approved for HIV-associated lipodystrophy.
View profileMitochondrially-encoded peptide with reported insulin-sensitizing activity.
View profileC-terminal hGH fragment (177–191) historically investigated for lipolysis.
View profileSmall-molecule NNMT inhibitor (often catalogued alongside peptides).
View profileThe most studied are incretin receptor agonists — GLP-1, dual GLP-1/GIP, and triple GLP-1/GIP/glucagon agonists — alongside amylin analogs. They act on satiety, insulin secretion, gastric emptying, and energy expenditure.
In studies they slow gastric emptying and signal satiety in the brain while improving glucose-dependent insulin release, which together reduce caloric intake and improve glycemic control.
Several GLP-1 and dual-agonist peptides are FDA-approved for type 2 diabetes and chronic weight management; others remain investigational. This page is a research reference, not medical advice.
How to weigh this evidence
Preclinical, observational, and randomized findings carry very different weight. The evidence hierarchy shows how to rank what you read before drawing conclusions.